HealthDay News — Enoxaparin is effective for prevention and treatment of venous thromboembolic events (VTEs) in patients with advanced pancreatic cancer (APC), according to a study published in the Journal of Clinical Oncology.
Uwe Pelzer, MD, PhD, from Universitätsmedizin Berlin, and colleagues randomized 312 patients with histologically proven APC to ambulant first-line chemotherapy and prophylactic use of enoxaparin (160 patients) or chemotherapy alone (152 patients).
The researchers found that within the first three months there were 15 symptomatic VTEs in the observation group and two in the enoxaparin group (hazard ratio, 0.12; 95% confidence interval [CI], 0.03 to 0.52; P = 0.001). There were five major bleeding events in the observation group and seven in the enoxaparin group (hazard ratio, 1.4; 95% CI, 0.35 to 3.72; P = 1.0). The overall cumulative incidence rates of symptomatic VTEs were 15.1 and 6.4% for the observation and enoxaparin groups, respectively (hazard ratio, 0.40; 95% CI, 0.19 to 0.83; P = 0.01). There were no significant between-group differences noted in progression-free (hazard ratio, 1.06; 95% CI, 0.84 to 1.32; P = 0.64) and overall survival (hazard ratio, 1.01; 95% CI, 0.87 to 1.38; P = 0.44).
“This study demonstrates the high efficacy and feasibility of primary pharmacologic prevention of symptomatic VTEs in outpatients with APC,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Amgen, Eli Lilly, and sanofi-aventis, which provided enoxaparin free of charge.